Myopharm Limited Email Formats

Biotechnology Research • Sydney, New South Wales, Australia • 1-10 Employees

Myopharm Limited Email Formats

Myopharm Limited uses 1 email format. The most common is {first name}{last name} (e.g., johndoe@myopharm.com), used 100% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@myopharm.com	100%

Key Contacts at Myopharm Limited

Karinza Phoenix

Executive Chair & Chief Executive Officer

Kevin Healey

Executive Director

Company overview

Headquarters	60 Martin Pl, Levels 1,2&3, Sydney, New South Wales 2000, AU
Phone number	+61285272453
Website	myopharm.com
Keywords	Biotechnology, Diabetes, R&D, Weightloss, Therapeutics, Endocrinology, Orphan / Rare Diseases, Pre-Diabetes, Insulin Resistance, Metabolic Diseases, T2D, Metabolic Syndromes, Type 2 Diabetes, Beta-Cell-Centric, Ind Approved
Employees	1-10
Socials

About Myopharm Limited

Myopharm Limited is a clinical-stage Australian-based biopharmaceutical company, developing targeted therapies for multiple chronic diseases. In our portfolio we have pharmaceutical drug candidates & clinically validated consumer health products. Our lead drug asset TriGlytza is at IND stage and as a biotechnology company we are focused on developing first-in-class, novel therapeutics and consumer products for the treatment and prevention of Type 2 diabetes. Myopharm is currently developing a number of diabetes therapeutics including a beta-cell-centric triple combination drug, to address the 50% antidiabetic treatment failures occurring in Type 2 diabetics. Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 or TriGlytza™ restored the efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring TriGlytza™ to market by 2027. https://www.myopharm.com